Mysore Venkataram, Shashikumar B M
Department of Dermatology, Venkat Charmalaya, Institute for Advanced Dermatology and Postgraduate Training, Bengaluru, Karnataka, India.
Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):128-34. doi: 10.4103/0378-6323.177432.
Finasteride is a widely used drug in dermatology for the treatment of androgenetic alopecia. There are many reports of associated sexual side effects. This article reviews the use of once-daily 1 mg finasteride in androgenetic alopecia and its associated sexual adverse effects.
A literature search was performed to collect data on the use of finasteride in male pattern baldness. Relevant literature published till March 2014 was obtained from MEDLINE, EMBASE, CINAHL, Cochrane registers and LILACS. The keywords "finasteride", "male pattern baldness" and "androgenetic alopecia" were used for literature search. Similarly, a search was done for finasteride in female pattern hair loss with keywords "female pattern baldness", "finasteride" and "female pattern alopecia". All systematic reviews, meta-analyses, national guidelines, randomized controlled trials, prospective open label studies and retrospective case series in the English literature were reviewed.
Two hundred sixty two studies were evaluated, twelve of which fulfilled the inclusion criteria.
Current evidence on the safety of finasteride indicates that it is safe but there is growing concern about its sexual side effects. In view of this, proper information should be provided to patients prior to starting treatment (Level of recommendation 1+, Grade of recommendation B). The reported sexual side effects are few and reverse with stoppage of the drug (Grade of recommendation B) but further studies are required.
非那雄胺是皮肤科广泛用于治疗雄激素性脱发的药物。有许多关于其相关性副作用的报道。本文综述了每日一次服用1毫克非那雄胺治疗雄激素性脱发及其相关性不良反应的情况。
进行文献检索以收集非那雄胺用于男性型秃发的数据。截至2014年3月发表的相关文献从MEDLINE、EMBASE、CINAHL、Cochrane注册库和LILACS获取。使用关键词“非那雄胺”“男性型秃发”和“雄激素性脱发”进行文献检索。同样，使用关键词“女性型秃发”“非那雄胺”和“女性型脱发”对非那雄胺用于女性型脱发进行检索。对英文文献中的所有系统评价、荟萃分析、国家指南、随机对照试验、前瞻性开放标签研究和回顾性病例系列进行了综述。
评估了262项研究，其中12项符合纳入标准。
关于非那雄胺安全性的现有证据表明它是安全的，但对其性副作用的担忧日益增加。鉴于此，在开始治疗前应向患者提供适当信息（推荐级别1+，推荐等级B）。所报道的性副作用较少，停药后可逆转（推荐等级B），但仍需要进一步研究。
